The aims of this study were twofold: (i) to evaluate MHL1 and MGMT methylation levels in OSCC and OPMD to ascertain their prognostic and clinicopathological significance in our institutional database and (ii) to integrate this information with The Cancer Genome Atlas (TCGA) database. This evidence concerns the gene MGMT and oculopharyngeal muscular dystrophy.